• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Long-term and low-dose of busulfan is a safe and effective second-line treatment in elderly patients with essential thrombocythemia resistant or intolerant to hydroxyurea.

作者信息

Renso Rossella, Aroldi Andrea, Pioltelli Pietro, Gambacorti-Passerini Carlo, Elli Elena Maria

机构信息

Hematology Division and Bone Marrow Unit, San Gerardo Hospital, Monza, Italy.

Department of Medicine, University of Milano-Bicocca, Monza, Italy.

出版信息

Blood Cancer J. 2018 Jun 11;8(6):56. doi: 10.1038/s41408-018-0091-6.

DOI:10.1038/s41408-018-0091-6
PMID:29891835
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5995877/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d58f/5995877/a585d117735b/41408_2018_91_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d58f/5995877/a585d117735b/41408_2018_91_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d58f/5995877/a585d117735b/41408_2018_91_Fig1_HTML.jpg

相似文献

1
Long-term and low-dose of busulfan is a safe and effective second-line treatment in elderly patients with essential thrombocythemia resistant or intolerant to hydroxyurea.长期低剂量白消安是对羟基脲耐药或不耐受的老年原发性血小板增多症患者安全有效的二线治疗方法。
Blood Cancer J. 2018 Jun 11;8(6):56. doi: 10.1038/s41408-018-0091-6.
2
Busulphan is safe and efficient treatment in elderly patients with essential thrombocythemia.白消安是治疗老年原发性血小板增多症的安全有效的疗法。
Leukemia. 2007 Sep;21(9):2071-2. doi: 10.1038/sj.leu.2404743. Epub 2007 Jul 5.
3
Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea.对于不耐受或抵抗羟基脲的真性红细胞增多症或原发性血小板增多症患者，使用白消安治疗。
Ann Hematol. 2014 Dec;93(12):2037-43. doi: 10.1007/s00277-014-2152-7. Epub 2014 Jul 2.
4
Busulfan is effective second-line therapy for older patients with Philadelphia-negative myeloproliferative neoplasms intolerant of or unresponsive to hydroxyurea.白消安是对羟基脲不耐受或无反应的费城染色体阴性骨髓增殖性肿瘤老年患者的有效二线治疗药物。
Leuk Lymphoma. 2017 Jan;58(1):89-95. doi: 10.1080/10428194.2016.1187269. Epub 2016 Jul 25.
5
Is hydroxyurea leukemogenic in essential thrombocythemia?羟基脲在原发性血小板增多症中会诱发白血病吗？
Blood. 1998 Aug 15;92(4):1459-60; author reply 1460-1.
6
Transition of essential thrombocythemia to megakaryoblastic leukemia after long-term therapy with sequential busulfan, pipobroman and hydroxyurea.长期序贯使用白消安、哌泊溴烷和羟基脲治疗后，原发性血小板增多症转变为巨核细胞白血病。
Acta Haematol. 2003;109(3):161-2. doi: 10.1159/000069288.
7
Second malignancies in essential thrombocythemia (ET): a retrospective analysis of 331 patients with long-term follow-up from a single institution.原发性血小板增多症（ET）中的第二原发性恶性肿瘤：来自单一机构的331例长期随访患者的回顾性分析
Hematology. 2008 Aug;13(4):195-202. doi: 10.1179/102453308X316022.
8
Leukemia and myelodysplasia in patients with essential thrombocythemia treated with cytotoxic agents.接受细胞毒性药物治疗的原发性血小板增多症患者中的白血病和骨髓增生异常综合征。
Haematologica. 1999 Nov;84(11):1049-50.
9
[Treatment of essential thrombocythemia--personal experience].[原发性血小板增多症的治疗——个人经验]
Pol Arch Med Wewn. 2000 Mar-Apr;103(3-4):179-85.
10
[Treatment outcome of patients with essential thrombocythemia at our department in Hungary].[匈牙利我们科室原发性血小板增多症患者的治疗结果]
Orv Hetil. 2016 Feb 28;157(9):336-41. doi: 10.1556/650.2016.30323.

引用本文的文献

1
Safety and Efficacy of Busulphan Based on Dosing Patterns in the Real-World Management of Myeloproliferative Neoplasms.基于骨髓增殖性肿瘤实际管理中给药模式的白消安安全性和有效性
EJHaem. 2025 Mar 19;6(2):e1097. doi: 10.1002/jha2.1097. eCollection 2025 Apr.
2
Polycythemia vera: historical oversights, diagnostic details, and therapeutic views.真性红细胞增多症：历史的忽视、诊断的细节和治疗的观点。
Leukemia. 2021 Dec;35(12):3339-3351. doi: 10.1038/s41375-021-01401-3. Epub 2021 Sep 3.
3
Developing strategies to reduce the duration of therapy for patients with myeloproliferative neoplasms.

本文引用的文献

1
Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.真性红细胞增多症和原发性血小板增多症：2017 年诊断、危险分层和治疗更新。
Am J Hematol. 2017 Jan;92(1):94-108. doi: 10.1002/ajh.24607.
2
Busulfan is effective second-line therapy for older patients with Philadelphia-negative myeloproliferative neoplasms intolerant of or unresponsive to hydroxyurea.白消安是对羟基脲不耐受或无反应的费城染色体阴性骨髓增殖性肿瘤老年患者的有效二线治疗药物。
Leuk Lymphoma. 2017 Jan;58(1):89-95. doi: 10.1080/10428194.2016.1187269. Epub 2016 Jul 25.
3
Busulfan for the treatment of myeloproliferative neoplasms: the Mayo Clinic experience.
制定策略以缩短骨髓增殖性肿瘤患者的治疗持续时间。
Expert Rev Hematol. 2020 Nov;13(11):1253-1264. doi: 10.1080/17474086.2020.1831381. Epub 2020 Oct 19.
白消安治疗骨髓增殖性肿瘤：梅奥诊所的经验
Blood Cancer J. 2016 May 27;6(5):e427. doi: 10.1038/bcj.2016.34.
4
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.2016 年版世界卫生组织髓系肿瘤和急性白血病分类。
Blood. 2016 May 19;127(20):2391-405. doi: 10.1182/blood-2016-03-643544. Epub 2016 Apr 11.
5
Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea.对于不耐受或抵抗羟基脲的真性红细胞增多症或原发性血小板增多症患者，使用白消安治疗。
Ann Hematol. 2014 Dec;93(12):2037-43. doi: 10.1007/s00277-014-2152-7. Epub 2014 Jul 2.
6
Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project.修订版原发性骨髓纤维化、真性红细胞增多症和原发性血小板增多症的反应标准：ELN 和 IWG-MRT 共识项目。
Blood. 2013 Jun 6;121(23):4778-81. doi: 10.1182/blood-2013-01-478891. Epub 2013 Apr 16.
7
Clinical evaluation of the European LeukaemiaNet criteria for clinicohaematological response and resistance/intolerance to hydroxycarbamide in essential thrombocythaemia.欧洲白血病网标准在原发性血小板增多症中对羟基脲临床血液学反应和耐药/不耐受的临床评估。
Br J Haematol. 2011 Jan;152(1):81-8. doi: 10.1111/j.1365-2141.2010.08430.x. Epub 2010 Nov 18.
8
Busulfan versus hydroxyurea in the treatment of polycythemia vera (PV) and essential thrombocythemia (ET).白消安与羟基脲治疗真性红细胞增多症（PV）和原发性血小板增多症（ET）的对比
Am J Clin Oncol. 1998 Feb;21(1):105-6. doi: 10.1097/00000421-199802000-00024.